Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer (Q36184256)

12 August 2017

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer (English)

1 reference

12 August 2017

metastatic breast cancer

1 reference

1 reference

F Cappuzzo

2

0 references

Alessandra Fabi

object named as

A Fabi

5

0 references

Terence J O'Brien

object named as

T O'Brien

6

0 references

0 references

4

J Jassem

1 reference

12 August 2017

G Minuti

1

1 reference

12 August 2017

R Duchnowska

3

1 reference

12 August 2017

A D Mendoza

7

1 reference

12 August 2017

L Landi

8

1 reference

12 August 2017

W Biernat

9

1 reference

12 August 2017

B Czartoryska-Arłukowicz

10

1 reference

12 August 2017

T Jankowski

11

1 reference

12 August 2017

D Zuziak

12

1 reference

12 August 2017

J Zok

13

1 reference

12 August 2017

B Szostakiewicz

14

1 reference

12 August 2017

M Foszczyńska-Kłoda

15

1 reference

12 August 2017

A Tempińska-Szałach

16

1 reference

12 August 2017

E Rossi

17

1 reference

12 August 2017

M Varella-Garcia

18

1 reference

12 August 2017

language of work or name

English

0 references

publication date

31 July 2012

1 reference

British Journal of Cancer

12 August 2017

1 reference

12 August 2017

107

1 reference

12 August 2017

5

1 reference

12 August 2017

793-799

1 reference

https://scigraph.springernature.com/pub.10.1038/bjc.2012.335

12 August 2017

0 references

cites work

cMET and phospho-cMET protein levels in breast cancers and survival outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Breast cancer-derived bone metastasis can be effectively reduced through specific c-MET inhibitor tivantinib (ARQ 197) and shRNA c-MET knockdown

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Adjuvant trastuzumab in HER2-positive breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Invasive growth: a MET-driven genetic programme for cancer and stem cells

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Synergistic effects of foretinib with HER-targeted agents in MET and HER1- or HER2-coactivated tumor cells.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3425981

Nonparametric Estimation from Incomplete Observations

23 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.335

Recurrent gene amplifications in human type I endometrial adenocarcinoma detected by fluorescence in situ hybridization

21 January 2018

1 reference

12 December 2020

Clinical Notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer

1 reference

12 December 2020

Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer

1 reference

12 December 2020

Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer

1 reference

12 December 2020

Expression of scatter factor and c-met receptor in benign and malignant breast tissue

1 reference

12 December 2020

Amplification of c-myc, K-sam, and c-met in gastric cancers: detection by fluorescence in situ hybridization

1 reference

12 December 2020

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue

1 reference

12 December 2020

Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma

1 reference

12 December 2020

Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.335

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/BJC.2012.335

1 reference

12 August 2017

1 reference

12 August 2017

1 reference